Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

177Lu-DOTATATE

  • You have access
    Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy (PRRT)
    Christopher E Wee, Ayca Dundar, Rachel A Eiring, Mohamed Badawy, Timothy J Hobday, Ayse Tuba Kendi, Annie T Packard and Thorvardur R. Halfdanarson
    Journal of Nuclear Medicine March 19, 2021, jnumed.121.262048; DOI: https://doi.org/10.2967/jnumed.121.262048
  • You have access
    Surgical feasibility, Determinants and overall Efficacy assessment of Neoadjuvant PRRT with 177Lu-DOTATATE for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
    Rahul V Parghane, Manish Bhandare, Vikram Chaudhari, Shailesh V Shrikhande, Vikas Ostwal, Anant Ramaswamy, Sanjay Talole and Sandip Basu
    Journal of Nuclear Medicine February 26, 2021, jnumed.120.258772; DOI: https://doi.org/10.2967/jnumed.120.258772
  • You have access
    Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
    Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming and Ghassan El-Haddad
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 69-72; DOI: https://doi.org/10.2967/jnumed.120.242875
  • You have access
    Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
    Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer and Peter Kletting
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 92-98; DOI: https://doi.org/10.2967/jnumed.120.245068
  • You have access
    In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Mark Lubberink, Helena Wilking, Amalia Öst, Ezgi Ilan, Mattias Sandström, Camilla Andersson, Katarzyna Fröss-Baron, Irina Velikyan and Anders Sundin
    Journal of Nuclear Medicine September 1, 2020, 61 (9) 1337-1340; DOI: https://doi.org/10.2967/jnumed.119.237818
  • Open Access
    Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
    Edward O’Neill, Veerle Kersemans, P. Danny Allen, Samantha Y.A. Terry, Julia Baguña Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens and Bart Cornelissen
    Journal of Nuclear Medicine May 1, 2020, 61 (5) 743-750; DOI: https://doi.org/10.2967/jnumed.119.232934
  • Open Access
    Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
    Linn Hagmarker, Johanna Svensson, Tobias Rydén, Martijn van Essen, Anna Sundlöv, Katarina Sjögreen Gleisner, Peter Gjertsson and Peter Bernhardt
    Journal of Nuclear Medicine October 1, 2019, 60 (10) 1406-1413; DOI: https://doi.org/10.2967/jnumed.118.225235
  • You have access
    Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, M. Konijnenberg, B.L. Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning and Dik J. Kwekkeboom
    Journal of Nuclear Medicine March 1, 2018, 59 (3) 452-458; DOI: https://doi.org/10.2967/jnumed.117.189712
  • You have access
    NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors
    Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson and Viktor Johanson
    Journal of Nuclear Medicine February 1, 2017, 58 (2) 288-292; DOI: https://doi.org/10.2967/jnumed.116.177584
  • You have access
    Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ezgi Ilan, Mattias Sandström, Cecilia Wassberg, Anders Sundin, Ulrike Garske–Román, Barbro Eriksson, Dan Granberg and Mark Lubberink
    Journal of Nuclear Medicine February 1, 2015, 56 (2) 177-182; DOI: https://doi.org/10.2967/jnumed.114.148437
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire